Charlotte Wilhelm Benartzi (Charlotte S Wilhelm-Benartzi)

Years Active: 2021-2024
Publications (10 Years): 2

This page only lists publications with an associated author ORCID identifier.

Publications

Alessandro Troiani, Maria Martinez, Caroline Ward, Charlotte Wilhelm Benartzi, David James Pinato, Rohini Sharma
Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL). Future oncology (London, England) (2024)
Charlotte Wilhelm Benartzi, Sarah E Miller, Sylvaine Bruggraber, Diane Picton, Mark Wilson, Katrina Gatley, Anita Chhabra, M Loredana Marcovecchio, A Emile J Hendriks, Hilde Morobé, Piotr Jaroslaw Chmura, Simon Bond, Bärbel Aschemeier-Fuchs, Mikael Knip, Timothy Tree, Lut Overbergh, Jaivier Pall, Olivier Arnaud, Michael J Haller, Almut Nitsche, Anke M Schulte, Chantal Mathieu, Adrian Mander, Professor David Dunger
Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes. BMJ open 11 (12) (2021)

Charlotte Wilhelm Benartzi.css-eqlu8i{font-size:small;padding-left:4px;} (Charlotte S Wilhelm-Benartzi)